2023
DOI: 10.1038/s41598-023-34128-5
|View full text |Cite
|
Sign up to set email alerts
|

Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections

Abstract: Intravitreal anti–vascular endothelial growth factor (anti-VEGF) agents have been increasingly applied in the treatment of retinal neovascular diseases. Concerns have arisen that these intravitreal agents may be associated with a potential risk of arterial thromboembolic (ATE) events. We conducted a retrospective, nationwide population‐based cohort study to analyze the risks for ATE events in patients receiving intravitreal ranibizumab (IVR) or intravitreal aflibercept (IVA). Data (2011–2018) were obtained fro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 48 publications
0
1
0
Order By: Relevance
“…Firstly, VEGF-induced nitric oxide (NO) production is inhibited, which suppresses NO-dependent vasodilation, antithromboticity, and angiogenesis. This clinically raises the risk of myocardial infarctions, strokes, venous thromboembolisms, and hypertension [82]. Furthermore, two of the most widely used anti-VEGF medications-ranibizumab and aflibercept-were confirmed in in vitro studies to increase the proinflammatory agent's concentration, playing a crucial role in atherosclerotic plaque formation [83].…”
Section: Mechanisms Underlying Cardiovascular Effectsmentioning
confidence: 99%
“…Firstly, VEGF-induced nitric oxide (NO) production is inhibited, which suppresses NO-dependent vasodilation, antithromboticity, and angiogenesis. This clinically raises the risk of myocardial infarctions, strokes, venous thromboembolisms, and hypertension [82]. Furthermore, two of the most widely used anti-VEGF medications-ranibizumab and aflibercept-were confirmed in in vitro studies to increase the proinflammatory agent's concentration, playing a crucial role in atherosclerotic plaque formation [83].…”
Section: Mechanisms Underlying Cardiovascular Effectsmentioning
confidence: 99%